close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

Medicare

Medicare typically covers and reimburses SYNVISC® in both the physician's office and hospital outpatient settings when the patient has documented knee pain due to osteoarthritis (OA), and has failed to respond to conventional therapies. Medicare does not require prior authorization.



SYNVISC is covered according to specific local coverage determinations (LCDs) that have been established by the regional Medicare carrier, and when administered "incident to" a physician's care. This means SYNVISC must:

  • Be provided by and represent a cost to the physician, and
  • Be administered in the physician's office by a physician or someone under the physician's supervision.

For billing instructions in the office setting:
Download the Sample CMS-1500 Claim Form (PDF, 225K).

Download more Forms & Sample Letters, including a Blank CMS-1500 Claim Form (PDF, 87K)

Competitive Acquisition Program (CAP)
The CAP is an optional program offered to physicians who do not wish to stock commonly billed drugs and biologics, such as SYNVISC, given in the physician office for Medicare patients. Instead, physicians may enroll in this program and order all CAP products exclusively through the CAP specialty vendor, BioScrip. CAP physicians no longer buy and bill for CAP products, except for emergent use or under special circumstances. CAP enrollment is offered annually. Once enrolled, CAP physicians bill their local Medicare carrier for the administration only. All Medicare Part B carrier local coverage decisions (LCDs) apply to SYNVISC administration and claims made through CAP.

Medicare Advantage Plans Medicare offers managed care insurance, known as Medicare Advantage (MA) plans, as an alternative to traditional Medicare Part B coverage. MA plans are administered by commercial insurers, and provide the scope of benefits offered under Part B, as well as supplemental benefits, such as coverage of Medicare premiums and deductibles, or prescription drug coverage. MA plans serve one or more entire regions, and have a network of contracted providers offering benefits at a uniform premium and level of cost-sharing to all Medicare beneficiaries residing in the MA plan service area. It is important to confirm your patient's specific MA plan benefits to understand coverage and reimbursement requirements for SYNVISC.

Questions about Medicare coverage?
SYNVISC ConnectionSM is staffed with a team of reimbursement specialists who can help you understand Medicare coverage and payment requirements for SYNVISC. You can reach SYNVISC Connection at 1-800-982-8292, M-F, 9am-6pm (EST).

Providers retain responsibility for determining reimbursement and insurance issues related to their patients. Genzyme cannot be responsible for failure of a provider to obtain reimbursement.




Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)